Holen Sie sich die Stockscreener-App
329.97
8.79%
-31.78
Vorhandelsmarkt:
334.00
4.03
+1.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$361.75
Offen:
$345
24-Stunden-Volumen:
3.23M
Relative Volume:
2.26
Marktkapitalisierung:
$64.19B
Einnahmen:
$321.33B
Nettoeinkommen (Verlust:
$1.57B
KGV:
41.50
EPS:
7.9518
Netto-Cashflow:
$3.21B
1W Leistung:
-5.87%
1M Leistung:
-2.63%
6M Leistung:
+12.37%
1J Leistung:
+31.16%
1-Tages-Spanne:
$328.01
$356.97
1-Wochen-Bereich:
$328.01
$366.15
52-Wochen-Spanne:
$237.71
$377.54
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Vergleichen Sie COR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
329.97 | 70.37B | 321.33B | 1.57B | 3.21B | 7.9518 |
|
MCK
Mckesson Corporation
|
822.00 | 105.05B | 387.09B | 4.23B | 6.01B | 32.12 |
|
CAH
Cardinal Health Inc
|
206.85 | 51.80B | 234.31B | 1.61B | 4.45B | 6.6243 |
|
HSIC
Henry Schein Inc
|
75.26 | 8.61B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.60 | 801.83M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
COR Q4 Deep Dive: Specialty Expansion and OneOncology Drive Strategic Shifts - Finviz
Cencora, Inc. (COR) Shares Slide as Revenue Miss Offsets Raised Operating Guidance - AlphaStreet
Decoding Cencora Inc (COR): A Strategic SWOT Insight - GuruFocus
Cencora (COR) Margin Stays Near 0.5% As High P/E Tests Bullish Growth Narratives - simplywall.st
Cencora Earnings Call: Specialty Strength, Guidance Raised - TipRanks
Jefferies reiterates Buy rating on Cencora stock, sees upside potential By Investing.com - Investing.com Nigeria
Cencora (COR) Q1 2026 Earnings Call Transcript - Fortune
Cencora Inc (COR) Q1 2026 Earnings Call Highlights: Strong US Gr - GuruFocus
Cencora, Inc. SEC 10-Q Report - TradingView
Leerink reiterates Outperform rating on Cencora stock, citing durable growth By Investing.com - Investing.com Canada
Leerink reiterates Outperform rating on Cencora stock, citing durable growth - Investing.com
Cencora Well-Positioned for Durable Long-Term Growth From Strong Demand and Specialty Investments - Morningstar
Cencora, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025 - marketscreener.com
Cencora Stock Down Despite Q1 Earnings Beat, Gross Margin Improves - Yahoo Finance
Cencora Lifts 2026 Sales Outlook Despite Q1 Revenue Miss - Benzinga
Cencora beats quarterly profit estimates on strong demand for specialty medicines - marketscreener.com
Cencora tops profit estimates as revenue comes in just shy of forecasts - MSN
Cencora Q1 2026 presentation: EPS beat overshadowed by revenue miss and stock drop - Investing.com
Earnings call transcript: Cencora Q1 2026 sees slight EPS beat, stock drops - Investing.com
Cencora (COR) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Cencora (COR) Q1 Earnings Top Estimates - Yahoo Finance
Cencora Earnings Report: Q1 Overview - Benzinga
Cencora (COR) Q1 Earnings: EPS Surpasses, Revenue Falls Short - GuruFocus
Cencora Completes OneOncology Acquisition, Lifts Guidance - TipRanks
CENCORA ($COR) Releases Q1 2026 Earnings - Quiver Quantitative
Cencora: Overview of First Fiscal Quarter Earnings - Bitget
Cencora beats on earnings, revenue slightly misses expectations By Investing.com - Investing.com Nigeria
Cencora beats on earnings, revenue slightly misses expectations - Investing.com
Cencora: Fiscal Q1 Earnings Snapshot - marketscreener.com
Cencora Inc earnings beat by $0.04, revenue fell short of estimates - Investing.com South Africa
Earnings Flash (COR) Cencora, Inc. Reports Q1 Revenue $85.93B, vs. FactSet Est of $86.06B - marketscreener.com
Earnings Flash (COR) Cencora, Inc. Posts Q1 Adjusted EPS $4.08 per Share, vs. FactSet Est of $4.05 - marketscreener.com
Fund Flows: What dividend growth rate does Cencora Inc offerJuly 2025 Action & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Cencora earnings on deck as specialty bet takes center stage By Investing.com - Investing.com Nigeria
Cencora earnings on deck as specialty bet takes center stage - Investing.com
Examining the Future: Cencora's Earnings Outlook - Benzinga
Cencora (COR) Reports Earnings Tomorrow: What To Expect - Finviz
CD&R, TPG's Covetrus in talks to buy Cencora's vet businessreport (COR:NYSE) - Seeking Alpha
Mediolanum International Funds Ltd Purchases 32,138 Shares of Cencora, Inc. $COR - MarketBeat
Mawer Investment Management Ltd. Reduces Stock Holdings in Cencora, Inc. $COR - MarketBeat
Thrivent Financial for Lutherans Cuts Holdings in Cencora, Inc. $COR - MarketBeat
Keybank National Association OH Grows Stake in Cencora, Inc. $COR - MarketBeat
Analysts lift ratings and price targets as Cencora, Inc. (COR)’s growth story gains momentum - MSN
Atle Fund Management AB Reduces Position in Cencora, Inc. $COR - MarketBeat
National Pension Service Purchases 15,355 Shares of Cencora, Inc. $COR - MarketBeat
Cencora Taps Lincoln Financial CEO for Board in Strategic Governance Move - MyChesCo
Cencora’s Quiet Rally: Is The Drug-Distribution Giant Still A Buy After A Powerful Run? - AD HOC NEWS
Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)'s Growth Story Gains Momentum - Finviz
Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)’s Growth Story Gains Momentum - Insider Monkey
Is Cencora’s Rare-Disease Commercialization Push With Curant Reshaping Its Investment Narrative (COR)? - Sahm
Exploring Analyst Estimates for Cencora (COR) Q1 Earnings, Beyond Revenue and EPS - Yahoo Finance Australia
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.11%
2.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):